Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]
News: Igor Puzanov
Vanderbilt-Ingram Cancer Center melanoma experts will hold a patient education symposium for melanoma survivors and caregivers on Saturday, March 10, from 9:30 a.m. to 2:30 p.m. in the Preston Research Building, Room 898J. The free symposium, co-sponsored by the Melanoma Research Foundation, is open to all melanoma patients, no matter where they received their treatment. […]
A clinical trial of a new experimental therapy for metastatic melanoma being tested at Vanderbilt and several other medical centers has shown positive results, including tumor shrinkage in the majority of patients. The results support previously reported positive data for the drug, known as PLX4032 (RG7204), in a much larger patient population where all responses […]
A new drug used to treat advanced melanoma patients with a specific genetic mutation in their tumors demonstrated significant tumor shrinkage in the majority of patients during a clinical trials.
Subscribe to our e-Newsletter to receive email updates: